THE IBN SINA PHARMACEUTICAL INDUSTRY PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 253.7 BDT | +0.28% |
|
+0.04% | -11.48% |
Valuation
| Fiscal Period: June | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 6,844 | 9,270 | 8,954 | 7,927 | - | - |
| Enterprise Value (EV) 1 | 6,844 | 9,270 | 8,954 | 7,927 | 7,927 | 7,927 |
| P/E ratio | 17.8 x | 15.3 x | 14.8 x | 11.6 x | 10.2 x | 8.57 x |
| Yield | - | - | - | 2.68% | 3.04% | 3.63% |
| Capitalization / Revenue | 1.11 x | - | 0.98 x | 0.71 x | 0.62 x | 0.55 x |
| EV / Revenue | 1.11 x | - | 0.98 x | 0.71 x | 0.62 x | 0.55 x |
| EV / EBITDA | - | - | 8.23 x | 6.33 x | 5.41 x | 4.79 x |
| EV / FCF | - | - | 46.7 x | 83.4 x | 20.1 x | 11.4 x |
| FCF Yield | - | - | 2.14% | 1.2% | 4.97% | 8.81% |
| Price to Book | - | - | 2.96 x | 2.23 x | 1.92 x | 1.65 x |
| Nbr of stocks (in thousands) | 30,540 | 31,244 | 31,244 | 31,244 | - | - |
| Reference price 2 | 224.1 | 296.7 | 286.6 | 253.7 | 253.7 | 253.7 |
| Announcement Date | 10/21/20 | 10/4/22 | 9/30/23 | - | - | - |
1BDT in Million2BDT
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 6,192 | - | 9,125 | 11,179 | 12,744 | 14,528 |
| EBITDA 1 | - | - | 1,088 | 1,252 | 1,466 | 1,656 |
| EBIT 1 | - | - | 860.4 | 1,015 | 1,133 | 1,302 |
| Operating Margin | - | - | 9.43% | 9.08% | 8.89% | 8.96% |
| Earnings before Tax (EBT) 1 | - | - | 804.7 | 910 | 1,033 | 1,228 |
| Net income 1 | - | 605.9 | 605.4 | 685 | 777 | 924 |
| Net margin | - | - | 6.63% | 6.13% | 6.1% | 6.36% |
| EPS 2 | 12.56 | 19.39 | 19.38 | 21.90 | 24.90 | 29.60 |
| Free Cash Flow 1 | - | - | 191.6 | 95 | 394 | 698 |
| FCF margin | - | - | 2.1% | 0.85% | 3.09% | 4.8% |
| FCF Conversion (EBITDA) | - | - | 17.62% | 7.59% | 26.88% | 42.15% |
| FCF Conversion (Net income) | - | - | 31.65% | 13.87% | 50.71% | 75.54% |
| Dividend per Share 2 | - | - | - | 6.800 | 7.700 | 9.200 |
| Announcement Date | 10/21/20 | 10/4/22 | 9/30/23 | - | - | - |
1BDT in Million2BDT
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2024 Q2 |
|---|---|
| Net sales | - |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) | - |
| Net income | - |
| Net margin | - |
| EPS 1 | 6.700 |
| Dividend per Share | - |
| Announcement Date | 2/6/24 |
1BDT
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | 192 | 95 | 394 | 698 |
| ROE (net income / shareholders' equity) | - | - | 21.5% | 20.7% | 20.3% | 20.7% |
| ROA (Net income/ Total Assets) | - | - | 13% | 12.6% | 12.7% | 13.9% |
| Assets 1 | - | - | 4,658 | 5,437 | 6,118 | 6,647 |
| Book Value Per Share 2 | - | - | 96.70 | 114.0 | 132.0 | 154.0 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 10/21/20 | 10/4/22 | 9/30/23 | - | - | - |
1BDT in Million2BDT
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
253.7
BDT
Average target price
370
BDT
Spread / Average Target
+45.84%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.48% | 72.19M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- IBNSINA Stock
- Financials The IBN SINA Pharmaceutical Industry PLC
